HK Stock Market Move | RIBOLIFE-B (06938) rose by over 6% in the morning, and achieved the first milestone in its siRNA collaboration project with Madrigal.

RIBOLIFE-B (06938) rose more than 6% in the morning, as of the time of writing, it rose by 5.49%, to 11.33 Hong Kong dollars, with a trading volume of 17.3845 million Hong Kong dollars. On the news front, on July 2, RIBOLIFE-B announced that the company has reached the first candidate drug selection milestone in its siRNA collaboration project with Madrigal. This collaboration aims to advance cutting-edge RNA therapy for liver diseases, with a focus on metabolic dysfunction-associated fatty liver disease (MASH). This milestone is the result of efficient collaboration between the two parties, and they will soon launch new drug clinical trial application (IND) supportive research to support future clinical research. MASH is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, requiring liver transplantation, and premature death. It is also the leading cause of liver transplantation in women and the second leading cause of liver transplantation in the United States. It is also the fastest growing indication for liver transplantation in Europe, affecting over 200 million people globally. RIBOLIFE-B and Madrigal aim to develop promising siRNA drugs targeting the liver using RiboGalSTARC platform, providing more targeted and effective treatment options for MASH patients with a huge medical need.